Net loss for the 12-month period ended December 31, 2008 was $25.2 million or $1.88 per share, as compared to $13.7 million or $1.09 per share, for the same period of 2007.
The increase in loss for the three-month and 12-month periods ended December 31, 2008 as compared to the same period in 2007 was primarily due to increased expenses in clinical development activities for Proellex and bulk compound manufacturing scale-up activities for Proellex, partially offset by a decrease in clinical and preclinical activities for Androxal.
The company reported total revenues of $28,000 for the fourth quarter of 2008, compared to $352,000 for the same period of 2007. For the full year 2008, Repros reported total revenues of $432,000, compared to $1.51 million for the full year 2007.